8-K: Lisata Therapeutics Reports Strong Q2, Advances Pipeline

Lisata Therapeutics announced positive clinical data for certepetide in solid tumors, extended its cash runway into Q4 2026, and reported reduced net losses for the second quarter of 2025.

Summary

• Lisata Therapeutics reported a net loss of $4.7 million for the second quarter ended June 30, 2025, an improvement from $5.0 million in the same period of 2024.
• Operating expenses decreased by 10.6% to $4.9 million in Q2 2025, down from $5.5 million in Q2 2024, driven by reductions in R&D and G&A costs.
• Revenue for Q2 2025 totaled $70 thousand, stemming from an upfront license fee related to a research agreement with Catalent, Inc.
• The company maintains a strong cash position with approximately $22.0 million in cash, cash equivalents, and marketable securities as of June 30, 2025, with no debt.
• Management reaffirmed that existing funds are projected to support current operations into the fourth quarter of 2026, covering all active clinical studies through their next data milestones.
• Preliminary data from the ASCEND Phase 2b trial's Cohort B showed a positive signal in progression-free survival (median PFS of 7.46 months vs. 4.65 months for placebo, HR 0.6, p=0.08) and objective response rate (45% vs. 19%) in metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The ASCEND Cohort A preliminary data indicated a positive trend in overall survival (median OS of 12.68 months vs. 9.72 months for placebo) and four complete responses in the certepetide-treated group.
• Enrollment in the BOLSTER Phase 2a trial for first-line cholangiocarcinoma was completed nearly six months ahead of schedule, accelerating topline data readout to Q4 2025.
• Enrollment in the BOLSTER Phase 2a trial's second-line cholangiocarcinoma cohort was stopped at approximately 20 patients to accelerate data readout and optimize capital allocation.
• The iLSTA Phase 1b/2a trial in locally advanced non-resectable PDAC completed enrollment, with updated interim analyses reinforcing certepetide's potential to enhance immunotherapy effectiveness.
• A new composition of matter patent (U.S. Patent No. 12,351,653) for certepetide was issued, extending patent protection until March 2040, with potential for further extensions.
• Lisata completed an End-of-Phase 2 FDA meeting and reached agreement on the Phase 3 program and development plan for certepetide in mPDAC, with a global Phase 3 trial planned for 657 patients.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, driven by compelling preliminary clinical data for certepetide in multiple solid tumor indications, particularly in pancreatic cancer where it shows strong signals of efficacy. The reaffirmation of an extended cash runway into late 2026, coupled with a new patent extending intellectual property protection, significantly de-risks the company's financial and strategic position. The successful FDA End-of-Phase 2 meeting and clear path to a pivotal Phase 3 trial for mPDAC are major milestones. While still a clinical-stage company with inherent risks, the progress and positive data warrant a strong sentiment.

Positives

• Net loss decreased to $4.7 million in Q2 2025 from $5.0 million in Q2 2024, indicating improved financial performance.
• Operating expenses reduced by 10.6% year-over-year, demonstrating effective cost management.
• Cash runway extended into the fourth quarter of 2026, providing sufficient funding for ongoing clinical programs without debt.
• Positive preliminary data from ASCEND Phase 2b Cohort B showed a clinically meaningful treatment effect in mPDAC, with a median PFS of 7.46 months versus 4.65 months for placebo (HR 0.6, p=0.08) and an ORR of 45% versus 19%.
• ASCEND Cohort A data showed a positive trend in overall survival (12.68 months vs. 9.72 months for placebo) and four complete responses in the certepetide arm.
• The iLSTA trial's updated interim analyses reinforced certepetide's potential to enhance immunotherapy effectiveness, showing significant RECIST responses and improved overall response and disease control rates.
• Early completion of enrollment for BOLSTER's first-line cholangiocarcinoma cohort accelerates topline data readout to Q4 2025.
• A new U.S. composition of matter patent for certepetide extends intellectual property protection until March 2040, with potential for further extensions.
• Successful End-of-Phase 2 FDA meeting resulted in agreement on the Phase 3 program and development plan for mPDAC, providing a clear regulatory path forward.
• Strategic partnerships with Catalent, GATC Health, Qilu Pharmaceutical, and Kuva Labs validate the CendR Platform technology and provide additional funding and development opportunities.

Negatives

• While improved, the company continues to report net losses, which is typical for a clinical-stage pharmaceutical company.
• The CENDIFOX trial, being investigator-initiated, has data timing not directly controlled by Lisata, introducing some uncertainty.

Risks

• Preliminary clinical data may not be indicative of final results, and outcomes could change following more comprehensive reviews or as more patient data becomes available.
• Product candidates that appear promising in early research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials.
• Decisions of regulatory authorities and the timing thereof, including potential regulatory delays in clinical programs, could impact development timelines.
• The ability to finance operations and the likelihood and timing of future milestone and licensing fees are subject to various factors.
• The future success of scientific studies and the ability to successfully develop and commercialize drug candidates are uncertain.
• Rapid technological change in the markets could impact the competitive landscape.
• The ability to protect intellectual property rights, including obtaining patent term extensions, is crucial.
• Legislative, regulatory, political, and economic developments could adversely affect the company's operations and financial condition.

Future Outlook

Lisata Therapeutics anticipates a number of additional data events through the remainder of 2025 and into 2026, including final data from the ASCEND study, topline data from BOLSTER, and final data from iLSTA. The company has reaffirmed its projection that available cash will fund current operations into the fourth quarter of 2026, including all active clinical studies through to their next data milestone. Preparations for a global Phase 3 clinical trial for certepetide in first-line metastatic pancreatic ductal adenocarcinoma are underway, following agreement with the FDA on the study design.

Management Comments

• "We continued to advance our clinical development portfolio and partnering initiatives during the second quarter of 2025."
• "All of our activities are to support our core mission of exploiting the broad applicability of certepetide across a variety of advanced solid tumors and other difficult-to-treat indications."
• "Our continued rigorous financial management allows us to reaffirm our projection that available cash will fund current operations into the fourth quarter of 2026, including all active clinical studies through to their next data milestone."

Industry Context

Lisata Therapeutics operates in the highly competitive clinical-stage pharmaceutical sector, focusing on advanced solid tumors, particularly pancreatic cancer, which is projected to become the second leading cause of cancer mortality by 2030. The company's certepetide aims to address the significant challenge of drug penetration into dense tumor microenvironments and overcome immunosuppression, which are major limitations for current standard-of-care treatments, including chemotherapies and immunotherapies. By enhancing the efficacy of existing anti-cancer agents, Lisata seeks to improve patient outcomes in areas with high unmet medical needs, positioning itself as a complementary rather than competitive player in the oncology landscape.

Comparison to Industry Standards

• Certepetide's ability to improve overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) in two independent Phase 1b/2a clinical trials (CEND1-001 in Australia and CEND1-201 in China) is akin to the efficacy observed with the recently FDA-approved NALIRIFOX triplet therapy, a significant benchmark in mPDAC treatment.
• The ASCEND Phase 2b Cohort A's median overall survival of 12.68 months for certepetide + SoC compared to 9.72 months for SoC alone shows a separation similar to that observed in the NAPOLI-3 study, which established NALIRIFOX as a standard.
• The potential for a Priority Review Voucher upon approval of certepetide for Rare Pediatric Disease Designation (osteosarcoma) is a valuable asset, with historical sales of such vouchers ranging from $75 million to $350 million, indicating a significant industry incentive for developing therapies for rare pediatric diseases.

Stakeholder Impact

• **Shareholders**: Positive clinical data, extended cash runway, and a clear path to Phase 3 for a lead asset could significantly enhance shareholder value and confidence.
• **Patients**: The advancement of certepetide, particularly with promising results in difficult-to-treat cancers like pancreatic and cholangiocarcinoma, offers hope for improved treatment outcomes and quality of life.
• **Employees**: The reaffirmed cash runway and active clinical development pipeline suggest stability and continued opportunities for the company's workforce.
• **Partners**: Ongoing collaborations and potential milestone payments (e.g., from Qilu Pharmaceutical) reinforce the value of existing partnerships and may attract new ones, benefiting all parties involved.

Next Steps

• Anticipated final data and key findings from both cohorts of the ASCEND study later this year (Q4 2025).
• Anticipated topline data readout for BOLSTER first-line cholangiocarcinoma in Q4 2025.
• CENDIFOX trial data expected in the coming months.
• Qilu Pharmaceutical's Phase 2 trial data for first-line mPDAC expected in the near future, with progression to Phase 3 triggering a $10 million milestone payment.
• Anticipated final data and key findings from the iLSTA trial in Q1 2026.
• Enrollment completion for the Phase 2a Glioblastoma Multiforme (GBM) study expected in 2026.
• Second EMA scientific advice meeting planned for Autumn 2025.
• Phase 3 preparations for certepetide in first-line mPDAC are underway.
• Preclinical evaluation of certepetide in combination with Catalent's SMARTag ADC platform, with data targeted for 2H 2025.
• Preclinical study with Valo Therapeutics assessing certepetide with an oncolytic virus and checkpoint inhibitor in melanoma, with data targeted for 2H 2025.
• Target first-in-human dosing for GATC-1021 asset for Opioid Use Disorder (OUD) (timing TBD).

Key Dates

Recommendation

The filing presents compelling positive clinical data for certepetide, particularly in metastatic pancreatic ductal adenocarcinoma (mPDAC), a high unmet need area, with results nearing statistical significance in key endpoints and showing complete responses. The company has a clear regulatory path forward with FDA agreement on a global Phase 3 trial design. Furthermore, the extended cash runway into Q4 2026, coupled with a new patent extending intellectual property protection until 2040, provides significant financial stability and long-term value. Multiple strategic partnerships further de-risk development and expand market opportunities. For a seasoned investor, these factors indicate strong potential for future growth and warrant a 'buy' recommendation, despite the inherent risks of a clinical-stage biotech.

Keywords

Certepetide, Pancreatic Cancer, Solid Tumors, Oncology, Clinical Trials, Biotechnology, Pharmaceuticals, SEC Filing, Financial Results, Drug Development, Metastatic Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma, Glioblastoma Multiforme, Immunotherapy, Chemotherapy, Orphan Drug, Fast Track Designation, Patent, Nasdaq